Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
During a recent taping of a business show on which I appear each week, I took some heat for making positive comments about the market?s little slide over the past several weeks. Some folks seemed to think it was odd that I would welcome having more investment opportunities, but I suppose it all ...